Literature DB >> 15511664

Chemoattractants and their receptors in homeostasis and inflammation.

Federica Sallusto1, Charles R Mackay.   

Abstract

The study of leukocyte migration continues to provide new insights into the regulation of lymphocyte priming in secondary lymphoid organs and effector responses in inflamed tissues. Chemoattractant receptors have always been viewed as facilitators of cell movement into a tissue. This whole concept must now be revised with the discovery of sphingosine 1 phosphate receptors, which control cell exit from lymphoid tissues. The chemoattractants that regulate lymphoid tissue homing are usually different to those that regulate leukocyte recruitment to inflamed tissues. There is evidence, however, of inflammatory pathways of leukocyte recruitment in lymph nodes and, conversely of constitutive pathways in peripheral tissues. Finally, antagonists (or agonists) of chemoattractant receptors and their signalling pathways represent the most attractive strategy for the treatment of a wide range of inflammatory diseases, including allergy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15511664     DOI: 10.1016/j.coi.2004.09.012

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  25 in total

Review 1.  Consider the chemokines: a review of the interplay between chemokines and T cell subset function.

Authors:  Marianne Strazza; Adam Mor
Journal:  Discov Med       Date:  2017-08       Impact factor: 2.970

Review 2.  Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications.

Authors:  Armen Yuri Gasparyan; Antonios Stavropoulos-Kalinoglou; Dimitri P Mikhailidis; Karen M J Douglas; George D Kitas
Journal:  Rheumatol Int       Date:  2011-02       Impact factor: 2.631

3.  CD3 expression distinguishes two gammadeltaT cell receptor subsets with different phenotype and effector function in tuberculous pleurisy.

Authors:  N Yokobori; P Schierloh; L Geffner; L Balboa; M Romero; R Musella; J Castagnino; G De Stéfano; M Alemán; S de la Barrera; E Abbate; M C Sasiain
Journal:  Clin Exp Immunol       Date:  2009-09       Impact factor: 4.330

Review 4.  Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors.

Authors:  Pawel Kalinski; Hideho Okada
Journal:  Semin Immunol       Date:  2010-04-20       Impact factor: 11.130

Review 5.  Dendritic cells in immunotherapy of established cancer: Roles of signals 1, 2, 3 and 4.

Authors:  Pawel Kalinski
Journal:  Curr Opin Investig Drugs       Date:  2009-06

6.  Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells.

Authors:  Thomas Duhen; Rebekka Geiger; David Jarrossay; Antonio Lanzavecchia; Federica Sallusto
Journal:  Nat Immunol       Date:  2009-07-05       Impact factor: 25.606

Review 7.  Dendritic cell-based therapeutic cancer vaccines: what we have and what we need.

Authors:  Pawel Kalinski; Julie Urban; Rahul Narang; Erik Berk; Ewa Wieckowski; Ravikumar Muthuswamy
Journal:  Future Oncol       Date:  2009-04       Impact factor: 3.404

8.  Peripheral blood CCR4+CCR6+ and CXCR3+CCR6+CD4+ T cells are highly permissive to HIV-1 infection.

Authors:  Annie Gosselin; Patricia Monteiro; Nicolas Chomont; Felipe Diaz-Griffero; Elias A Said; Simone Fonseca; Vanessa Wacleche; Mohamed El-Far; Mohamed-Rachid Boulassel; Jean-Pierre Routy; Rafick-Pierre Sekaly; Petronela Ancuta
Journal:  J Immunol       Date:  2009-12-30       Impact factor: 5.422

9.  Identification of a distal tandem STAT6 element within the CCL17 locus.

Authors:  Elisabeth Maier; Gerald Wirnsberger; Jutta Horejs-Hoeck; Albert Duschl; Daniel Hebenstreit
Journal:  Hum Immunol       Date:  2007-11-26       Impact factor: 2.850

Review 10.  Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis.

Authors:  Reshmi Roy; Alaa A Alotaibi; Mark S Freedman
Journal:  CNS Drugs       Date:  2021-04-02       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.